|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Not specified
|
|
|
|
Other
|
|
|
|
HSC-MS-06-0478 OSP-24412, NCT00581425
|
|
|
|
|
|
|
|
Last Modified: 1/7/2009  First Published: 2/27/2008 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Biomarker/Laboratory analysis, Diagnostic, Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
DUMC-PRO00000580 PRO00000580, DUMC-SPORE Project 3, NCT00627224
|
|
|
|
|
|
|
|
Last Modified: 11/17/2008  First Published: 3/13/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
16 and over
|
|
|
|
NCI
|
|
|
|
NCI-06-C-0069 7676, NCI-7676, NCI-P6703, NCT00304057
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Supportive care
|
|
|
|
Active
|
|
|
|
Not specified
|
|
|
|
Other
|
|
|
|
Eudract number: 2006-004902-16 LREC number: 06/Q2201/143, NCT00596336
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
CYT004-MelQbG10 04 NCT00651703
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI, Other
|
|
|
|
07-380 NCT00799110
|
|
|
|
|
|
|
|
First Published: 1/12/2009 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Approved-not yet active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
UWCC-6578 UWCC-6578, FHCRC-6578, IR-6578
|
|
|
|
|
|
|
|
First Published: 11/6/2008 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Biomarker/Laboratory analysis, Prevention, Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
JHOC-J0656 J0656, NA_00002176, NCT00788164
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Natural history/Epidemiology, Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
01 KI 0211 NCT00365729
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Treatment
|
|
|
|
Approved-not yet active
|
|
|
|
49 to 89
|
|
|
|
Other
|
|
|
|
WN07DE002 EudraCT No: 2007-001961-14, NCT00463359
|
|
|
|